Citius Pharmaceuticals, Inc. CTXR
Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care
products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to
achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk
than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety
Last close
0.40
2026-10-23
Market cap
$11.1M
2026-06-30 share count
52-week range
0.37 - 1.83
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.38
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $90.0K | $90.0K | $90.0K | $90.0K | $75.0K | $50.0K | — |
| Cost of revenue | — | — | — | — | — | — | — | $75.0K | $50.0K | $45.0K |
| Gross profit | — | — | — | — | — | — | — | $0 | $0 | — |
| R&D | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M | $8.8M | $8.6M | $6.6M | $2.9M | $2.9M |
| SG&A | $18.5M | $18.2M | $15.3M | $11.8M | $9.8M | $8.1M | $6.3M | $6.4M | $6.1M | $3.8M |
| Total operating expenses | $38.5M | $42.0M | $36.7M | $33.3M | $23.5M | $17.7M | $15.6M | $13.8M | $10.0M | $7.4M |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M | -$17.7M | -$15.6M | -$13.8M | -$10.0M | -$7.4M |
| Interest expense | $267.8K | — | — | — | $10.8K | $15.7K | $16.4K | $15.8K | $850.8K | $9.0K |
| Pre-tax income | -$38.7M | -$38.8M | -$32.0M | -$33.1M | -$23.1M | -$17.5M | -$15.6M | $12.5M | $10.4M | -$8.3M |
| Income tax | $1.1M | $576.0K | $576.0K | $576.0K | $1.2K | $741 | — | — | — | — |
| Net income | -$39.7M | -$39.4M | -$32.5M | -$33.6M | -$23.1M | -$17.5M | -$15.6M | -$12.5M | -$10.4M | -$8.3M |
| EPS, basic | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | — | — | — | — | — |
| EPS, diluted | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 |
| Shares, diluted (wtd. avg.) | 11.1M | 6.7M | 6.1M | 146.1M | 108.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294.4K |
| Inventory | $22.3M | $8.3M | — | — | — | — | — | — | — | — |
| Total current assets | $27.9M | $14.2M | $34.4M | $44.6M | $72.8M | $14.0M | $7.9M | $10.1M | $3.4M | $892.8K |
| Property, plant and equipment | — | — | $1.4K | $4.1K | $7.0K | $1.6K | $590 | $1.5K | $3.2K | $3.7K |
| Goodwill | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $1.6M | $1.6M | $1.6M |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M | $43.8M | $36.7M | $31.1M | $24.4M | $22.0M |
| Accounts payable | $13.7M | $4.9M | $2.9M | $1.2M | $1.3M | $1.9M | $2.7M | $1.6M | $602.4K | $909.2K |
| Total current liabilities | $44.9M | $35.8M | $5.8M | $4.5M | $4.0M | $4.1M | $4.6M | $3.2M | $2.5M | $5.2M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M | $10.1M | $9.6M | — | — | — |
| Retained earnings | -$238.8M | -$201.4M | -$162.2M | -$129.7M | -$96.0M | -$70.6M | -$53.0M | -$40.3M | -$27.7M | -$17.3M |
| Total equity | $67.6M | $70.1M | $91.4M | $103.4M | $132.8M | $33.7M | $27.2M | $30.6M | $21.9M | $16.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M | -$16.9M | -$12.4M | -$11.3M | -$8.0M | -$5.9M |
| Depreciation and amortisation | — | $1.4K | $2.7K | $2.9K | $1.5K | $844 | $893 | $1.8K | $2.6K | $1.3K |
| Stock-based compensation | $10.8M | $11.8M | $6.6M | $3.9M | $1.5M | $803.3K | $716.0K | $779.7K | $986.6K | $732.2K |
| Capital expenditure | — | — | — | — | $6.9K | $1.8K | — | — | $2.1K | — |
| Investing cash flow | -$5.8M | -$5.0M | — | — | -$40.0M | -$1.8K | — | — | -$2.1K | $255.7K |
| Financing cash flow | $33.3M | $10.0M | $13.8M | — | $120.5M | $22.9M | $11.1M | $17.3M | $10.9M | $5.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-008861.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $50.0K | $75.0K | $90.0K | $90.0K | $90.0K | $90.0K | — | — | — |
| Gross profit | — | $0 | $0 | — | — | — | — | — | — | — |
| Net income | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.4M | -$39.7M |
Recent filings and events
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |